Chronic pain affects one in five of the general population and is the third most important
cause of disability-adjusted life-years globally. Unfortunately, treatment remains inadequate …

Since the discovery of an acute monophasic paralysis, later coined Guillain–Barré
syndrome, almost 100 years ago, and the discovery of chronic, steroid-responsive …

Hyperexcitability in sensory neurons is known to underlie many of the maladaptive changes
associated with persistent pain. Chemogenetics has shown promise as a means to suppress …

Valid, responsive blood biomarkers specific to peripheral nerve damage would improve
management of peripheral nervous system (PNS) diseases. Neurofilament light chain (NfL) …

Neurodegenerative diseases represent a significant unmet medical need in our aging
society. There are no effective treatments for most of these diseases, and we know …

Objective Antibodies to myelin oligodendrocyte glycoprotein (MOG) are associated with
CNS demyelination inclusive of optic neuritis (ON) and transverse myelitis (TM). To examine …

Genetic pain loss includes congenital insensitivity to pain (CIP), hereditary sensory
neuropathies and, if autonomic nerves are involved, hereditary sensory and autonomic …

Human adipose‐derived stem cells (ASCs) have a potential for the treatment of peripheral
nerve injury. Recent studies demonstrated that stem cells can mediate therapeutic effect by …

Loss-of-function mutations in Na V 1.7 cause congenital insensitivity to pain (CIP); this
voltage-gated sodium channel is therefore a key target for analgesic drug development …

Primary rodent neurons and immortalised cell lines have overwhelmingly been used for in
vitro studies of traumatic injury to peripheral and central neurons, but have some limitations …